Clinical bottom line
Telehealth has emerged as a valuable tool in managing pulmonary arterial hypertension (PAH) during the COVID-19 pandemic, facilitating continuity of care while minimizing infection risk. Remote monitoring, virtual consultations, and digital symptom tracking have demonstrated benefits in patient engagement and early detection of clinical deterioration. However, barriers including technology access, reimbursement challenges, and limited physical examination capabilities persist. Optimizing telehealth integration into PAH management requires addressing these limitations and validating remote assessment tools to ensure safe, effective care (McDevitt et al., 2025).
What the evidence shows
McDevitt et al. (2025) provide a comprehensive review of telehealth’s role in PAH management, highlighting benefits such as improved access to specialized care, enhanced patient monitoring through wearable devices, and reduced hospital visits during the pandemic. Their analysis underscores telehealth’s potential to detect early signs of decompensation via remote symptom reporting and functional assessments.
Additional literature on telehealth during COVID-19 emphasizes its rapid adoption across chronic respiratory diseases, demonstrating feasibility and patient satisfaction despite initial implementation challenges (Bouabida et al., 2022). These studies report that telehealth can maintain disease control and support medication adherence when in-person visits are limited.
However, McDevitt et al. also identify barriers including disparities in digital literacy, variable internet access, and reimbursement uncertainties that may limit equitable telehealth delivery. The inability to perform comprehensive physical exams remotely remains a critical limitation.
Caveats and uncertainty
Most evidence derives from observational studies or expert opinion rather than randomized controlled trials specific to PAH.
Long-term outcomes comparing telehealth with traditional care models in PAH remain unclear.
Heterogeneity in telehealth platforms and monitoring tools complicates standardization.
Patient populations with limited technology access may be underserved.
Physical examination and invasive hemodynamic assessments cannot be fully replaced by telehealth.
How this may change practice
Clinicians should consider incorporating telehealth as a complementary modality for routine follow-up and symptom monitoring in PAH, particularly when in-person visits pose risks.
Development and validation of remote assessment tools, including wearable sensors and patient-reported outcome measures, are priorities.
Health systems should address infrastructure, training, and reimbursement policies to support sustainable telehealth integration.
Telehealth may facilitate multidisciplinary care coordination and patient education, enhancing self-management.
Ongoing evaluation of telehealth’s impact on clinical outcomes will inform best practices post-pandemic.